Manuel Pedregal

Medical Oncologist. Clinical Investigator at FJD START Phase 1 UNIT

[Angela Lamarca @DrAngelaLamarca]

Y de repente… 💥💥💥

Te llega financiación de un #ProyectoEuropeo!

Y ves la baja maternal y subes a #contrato de 1 año (posible 2 años).
Con 2 días #investigación y 3 de #asistencia en tumores #gastroesofagicos y #páncreas en @Hospital_FJD

📧: [email protected]

[Angela Lamarca @DrAngelaLamarca]

I am delighted to announce that @Hospital_FJD has been officially recognised as an @ENETS_ORG #CentreOfExcellence for #NeuroendocrineTumours both for #GEP and #Lung 🥳

Thank you to the whole FJD-NET team

Bringing the best care to our patients

#ThinkZebra @GrupoGetne @Netespana

[Angela Lamarca @DrAngelaLamarca]

Empezamos el 2026 anunciando 2️⃣ #puestos de #OncólogoMédico en el @Hospital_FJD 🥳

A elegir 😊 entre:
👉Pulmon +/- Cabeza y Cuello
👉Mama

Esperamos tu CV 😉

Detalles de los puestos vacantes: https://t.co/nxgZ6PrUDC

[Angela Lamarca @DrAngelaLamarca]

💚💚💚

[Angela Lamarca @DrAngelaLamarca]

Invikafusp alfa (selective dual T Cell agonist) phase I trial presented at @myESMO #ESMOGI25 by #ElenaElez

23.5% ORR - GI tumours (25% in CRC)

👉FDA Fast Track Designation for hTMB CRC
👉Phase II dose expansion ongoing

@mpedregal @TheSTARTCenter @Hospital_FJD

#ESMOAmbassadors

[Angela Lamarca @DrAngelaLamarca]

🚨#Job offer🚨

Immediate incorporation

“Clinical Research Fellow” in #MedicalOncology in hepato-pancreato-biliary and neuroendocrine tumours- research (80%) - patient care (20%)

Info: https://t.co/tJJbFiKW40

Email: [email protected]
🤝

@myESMO @ENETS_ORG

[Manuel Pedregal @mpedregal]

While innovation in breast and lung cancer has advanced rapidly, CRC lags behind, particularly in addressing KRAS mutations, improving immunotherapy responses, and identifying novel molecular targets… ⁦@Hospital_FJD⁩ ⁦@TheSTARTCenter⁩ https://t.co/wqdjVdC9q6

[Manuel Pedregal @mpedregal]

Poster presented at #ESMOTAT2025

Checking out the toxicity profile of our patients under epigenetic therapies at START-FJD Madrid. New early phase units will be joining the project to better characterize each drug type.

Thanks to the team! @VicMorenoGarcia @myESMO

[Angela Lamarca @DrAngelaLamarca]

Seguimos creciendo 💪
#OncologiaMedica @Hospital_FJD

La #investigación 🕵🏻‍♀️ es la 🔑 a un #futuro mejor para nuestros pacientes 🫂

@BrotoJavier @nadiahindi83 @VicMorenoGarcia @ManuelDomine @jaimerubiop @imanolex @dianaroseroo @EvaRuizHispan @mpedregal @alicastletree (y mas 😉)

[Angela Lamarca @DrAngelaLamarca]

🚨Great News!!

#Pembrolizumab with #CisGem now a #reimbursed first-line option for advanced #BiliaryMalignancies in #Spain

https://t.co/uXNhAgZ9LT

👀 Ivosidenib…

@atuvibi @GrupoTTD

[Angela Lamarca @DrAngelaLamarca]

14 years ago I went to #ESMO12 in Viena to the @myESMO #Fellowship award ceremony to start (2013) my #CareerDevelopment in HPB-NET at @TheChristieNHS, with the best #mentor ever, #ProfJuanValle

Now back in #Madrid in @Hospital_FJD, 📸 from #ESMO24

#MENTORS ARE #FOREVER🙌🏻

[Angela Lamarca @DrAngelaLamarca]

What an honour to be able to discuss the LEAP-12 trial in #HCC in @myESMO #ESMO24

🙋🏻‍♀️My thoughts in slides below
🫵Which are your thoughts?

#ESMOAmbassadors

[Roche+ @Roche_Plus]

¿Cómo las nuevas tecnologías ayudan al manejo del #hepatocarcinoma? Esta y otras preguntas obtienen respuesta en #LiverForum con la @DrAngelaLamarca, oncóloga médica del @Hospital_FJD y el periodista Pepe Ribagorda (@joseribagorda). 
 ¡No te lo pierdas! 🎬 https://t.co/Ed9Y3zGVgQ

[Angela Lamarca @DrAngelaLamarca]

Thank you to my co-chair @tgruenberger and our 🔝 panel #JohnBridgewater, @LorenzaRimassa and @rachnatshroff for this 🤩 #ESMOGI24 session in #Biliary

🔪+ Adj capecitabine
Neo-adj 🙏 trials
Ampullary 🧐
CisGem➕IO
NGS ➡️ targeted

@myESMO @CcaEns @sapisochin
#ESMOAmbassadors

[Arndt Vogel @ArndtVogel]

Phase I study of the PKMYT1 inhibitor lunresertib in combination with FOLFIRI in advanced GI cancers #ESMOGI24
🔎MINOTAUR study
👉Interesting MOA, for 20% of pts w/ CCCN1 amp or mFBXW7 >synthetically lethality
👉acceptable safety, "promising" efficacy
@myESMO

[Angela Lamarca @DrAngelaLamarca]

Huge congrats 👏🏻 to @andreamartirena, our trainee in #MedicalOncology at @Hospital_FJD, for her #poster in #ESMOGI24

‼️ #Diagnostic pathway for #pancreatic and #biliary cancer MUST improve! Details in comments 👇

@curecc @CharityAMMF @atuvibi @ACanPan @myESMO #ESMOAmbassadors

[Angela Lamarca @DrAngelaLamarca]

#MINOTAUR trial presented by @ElisaFontana83 at #ESMOGI24

#PKMYT1 inhibitor + FOLFIRI in
CCNE1 amplified and FBXW7 mutated #GICancers (Biliary, Pancreas and NET included 😉)

@GrupoTTD @myESMO @VicMorenoGarcia @mpedregal

#ESMOAmbassadors

[Angela Lamarca @DrAngelaLamarca]

Coming soon!! 2️⃣8️⃣th Febr 2024

@myesmo #fellowships are a fantastic opportunity to explore new frontiers 😉

Dial in and learn more 📝

[ESMO - Eur. Oncology @myESMO]

📣 Register now for the Biliary Tract Cancer webinar and get valuable insights from real-world cases.
⏲️ 27 February 2024 at 18:30 CET
#ESMOGuidelines Webinar https://t.co/OnBj06GIAz
@DucreuxMichel @mpedregal @ArndtVogel

[Angela Lamarca @DrAngelaLamarca]

Join us on the 15th February 2024 for the launch of #ATUVIBI, the #Spanish #BiliaryCancer #PatientAdvocate group

Your #support would mean so much!
😊

https://t.co/ZP1pyfX5rN

@Hospital_FJD @GrupoTTD @myESMO @_SEOM